By Budi Oetomo Narendra 
A landmark study, leveraging decades of patient data and advanced genomic sequencing, has illuminated critical genetic differences in chronic blood cancers, distinguishing between cases that remain stable and those destined to progress into more aggressive forms. These pivotal findings, recently published in the esteemed journal Cancer Discovery and also presented at the American Association of Cancer Research (AACR) Conference in San Diego, suggest a transformative shift in how myeloproliferative neoplasms (MPNs) are diagnosed, monitored, and treated. The research, spearheaded by scientists at the Wellcome Sanger Institute in collaboration with clinical partners, provides a roadmap for clinicians to potentially predict disease progression years before physical symptoms manifest, and even to reconsider certain diagnoses, sparing some patients from unnecessary anxiety and treatment.
Understanding Myeloproliferative Neoplasms: A Complex Landscape
Myeloproliferative neoplasms (MPNs) represent a group of rare, long-lasting blood cancers originating in the bone marrow, the soft, spongy tissue inside bones responsible for producing all blood cells. In individuals afflicted with MPNs, the bone marrow generates an excess of specific types of blood cells—red blood cells, white blood cells, or platelets—in an uncontrolled manner. This overproduction can lead to a range of complications, from blood clots and bleeding to fatigue and an enlarged spleen. The three main types of MPNs are Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF), each characterized by distinct cellular abnormalities but sharing common genetic drivers and the potential for transformation into more aggressive diseases, such as acute myeloid leukemia (AML) or secondary myelofibrosis.
The prevalence of MPNs, though considered rare, is significant. Approximately 40,000 individuals in the UK are currently living with these conditions, with an estimated 4,000 new diagnoses made each year. Globally, incidence rates vary, but the challenges in diagnosis and long-term management are universal. A defining characteristic of MPNs is their often slow and insidious progression. The journey typically begins with an initial genetic mutation, or a change in DNA, which can arise very early in life. Over the ensuing decades, additional mutations accumulate, gradually altering the behavior of blood cells and influencing the disease’s trajectory. This multi-step evolutionary process underscores the chronic nature of these cancers and the complexity in predicting their future course.
Current diagnostic protocols for MPNs often rely on identifying specific genetic mutations in genes such as JAK2, CALR, or MPL, which are present in the vast majority of patients. However, a significant minority—around 10 percent—of patients do not exhibit any of these common genetic changes. In these challenging cases, diagnosis has historically relied more heavily on the morphological examination of bone marrow cells and other clinical features. This approach, while necessary, can lead to diagnostic uncertainty, potentially resulting in patients receiving cancer treatments, including chemotherapy, without definitive genetic confirmation of an underlying MPN. This ambiguity highlights a critical need for more precise diagnostic tools and a clearer understanding of the genetic landscape of these atypical presentations.
The Enigma of Progression: Why Some Worsen and Others Remain Stable
One of the most perplexing aspects of chronic blood cancers like MPNs is the wide variability in patient outcomes. Some individuals experience years of stable disease, requiring only mild interventions to manage symptoms and maintain quality of life. Conversely, others eventually face a more ominous path, with their condition progressing to more severe states, such as the life-threatening leukemia or myelofibrosis, which involves extensive scarring of the bone marrow and can lead to bone marrow failure. The ability to distinguish between these two divergent paths early on has long eluded clinicians, making it difficult to tailor treatment strategies and provide accurate prognoses.
Driven by this clinical imperative, the research team embarked on an ambitious investigation to determine whether specific genetic changes could serve as reliable indicators of disease risk and progression. Furthermore, they sought to critically re-evaluate whether patients lacking the hallmark MPN mutations truly had a bona fide blood cancer or if their presentation reflected an entirely different biological phenomenon.
The study’s methodology was exceptionally rigorous and comprehensive, setting a new standard for longitudinal cancer research. Researchers meticulously followed a cohort of 30 patients diagnosed with chronic blood cancers, predominantly MPNs, for an extended period, with some individuals monitored through routine clinical care for an astounding 25 years. This unprecedented long-term follow-up was meticulously combined with state-of-the-art whole-genome sequencing and an exhaustive collection of clinical information. The dataset included nearly 8,000 individual blood test results, detailed treatment records, and extensive disease progression data. Over 450 distinct samples from these patients were subjected to repeated genomic testing, allowing scientists to track the genetic evolution of their blood cells over time with unparalleled resolution.
This unique partnership between the Wellcome Sanger Institute’s cutting-edge genomic research capabilities and the long-standing patient care provided by Cambridge University Hospitals NHS Foundation Trust proved instrumental. It enabled the scientists to observe the dynamic changes in blood cell populations and reconstruct the intricate evolutionary pathways of cancer development within each patient.
Building Genetic ‘Family Trees’ to Chart Cancer’s Evolution
A cornerstone of the study’s innovative approach involved constructing genetic ‘family trees’ of blood cells using DNA extracted from patient blood samples. These sophisticated phylogenetic reconstructions allowed the researchers to trace the origins and clonal expansion of cancer cells—groups of genetically identical cells that arise from a single ancestral cell and subsequently drive disease progression. By mapping these genetic lineages, the team gained an unprecedented view into how different blood cell populations evolved over decades.
The detailed analysis revealed strikingly distinct patterns of genetic evolution correlating with clinical outcomes in MPN patients. Individuals whose disease remained clinically stable over the long term tended to exhibit genetically ‘steady’ blood cell populations. These stable clones acquired few, if any, additional mutations beyond the initial cancer-driving event. In stark contrast, patients whose disease eventually progressed to more severe forms demonstrated a clear pattern of accumulating new and diverse DNA changes over time. These secondary mutations, often occurring years or even decades after the initial diagnosis, appeared to fuel the cancer’s accelerated evolution and drive its transformation.
This profound discovery suggests that the propensity for progression in chronic blood cancers may be biologically ‘encoded’ within the genetic landscape of a patient’s cells long before any visible clinical deterioration occurs. The mutations linked to future progression could potentially be detectable through genomic testing years in advance, preceding the onset of worsening symptoms or significant changes identifiable by standard clinical tests. This opens up a remarkable window of opportunity for proactive intervention.
Challenging Assumptions: When a Cancer Diagnosis Might Be Normal Aging
Beyond the insights into disease progression, the study also yielded groundbreaking findings with significant implications for diagnostic practices, particularly for patients who lack the common JAK2, CALR, or MPL mutations. The researchers meticulously reconstructed genetic ‘family trees’ from approximately 200 blood cell genomes belonging to these atypical patients. Instead of observing genetic patterns characteristic of cancer, which typically involve clonal expansion driven by specific oncogenic mutations, the scientists identified genetic changes that were far more consistent with the natural process of normal aging.
This finding fundamentally challenges a long-held assumption: that everyone presenting with certain unusual bone marrow features and an elevated platelet count (thrombocytosis), but without the canonical MPN mutations, necessarily has a true blood cancer. The research suggests that some individuals currently placed in this "MPN, triple-negative" category may, in fact, have biological characteristics that are distinct from genuine MPNs, possibly representing age-related clonal hematopoiesis—a common phenomenon where small populations of blood cells acquire mutations but do not necessarily lead to overt cancer.
The implications of this re-evaluation are profound. Doctors may need to reconsider how these patients are initially diagnosed and subsequently managed. This research provides crucial scientific backing for new guidelines recently issued by the British Society for Haematology (BSH), which recommend a more cautious approach. These guidelines propose that some patients initially be described as having "thrombocytosis without JAK2, CALR, or MPL mutations" rather than being immediately diagnosed with blood cancer. Thrombocytosis simply means a high platelet count. This nuanced diagnostic approach aims to prevent the emotional distress and potential overtreatment associated with a cancer diagnosis when the underlying biology may be more benign or age-related. It represents a significant step towards more precise and patient-centered care.
Toward Regular Genomic Monitoring: The Future of MPN Care
The study powerfully underscores the immense clinical benefits that could arise from integrating genomic information more routinely into cancer care. The potential applications are multifaceted and far-reaching. Genetic testing could empower doctors to more accurately distinguish between stable disease, which may require minimal intervention, and cancers that carry a high likelihood of progression, necessitating closer monitoring or earlier, more aggressive treatment. It could also refine uncertain diagnoses, providing clarity for patients and guiding the development of increasingly precise and personalized therapeutic strategies.
In the not-too-distant future, the vision is for regular genomic tests to become a standard component of patient care for MPNs. Such monitoring could enable clinicians to identify high-risk patients years before their disease visibly worsens or current standard-of-care tests indicate a significant change. This proactive approach would create unprecedented opportunities for early intervention, potentially altering the course of the disease and improving long-term outcomes. Equally important, it would help in avoiding unnecessary treatments for individuals whose blood changes might not be cancerous, thereby reducing treatment burden, side effects, and healthcare costs.
Dr. Daniel Leongamornlert, the first author from the Wellcome Sanger Institute, articulated the study’s elegance: "We followed patients with myeloproliferative neoplasms over many years and used genome sequencing and clinical history to trace how blood cell populations changed over time. By reconstructing the ancestry of cells, we were able to see different evolutionary patterns between patients who had stable disease compared to others who progressed." This longitudinal, cell-level perspective is what truly unlocked the predictive power of their findings.
Dr. Dani Skirrow, Research Information Manager at Cancer Research UK, a key funder of the study, emphasized the broader context: "We’re in a golden age of research where advances in technology mean we can rapidly read DNA to find the errors in the code that can lead to cancer. Collaboratively, our researchers have read huge amounts of DNA to build up a detailed picture of how certain blood cancers can start, grow and behave, revealing some changes that could help us predict cancer years in advance. This type of discovery research is essential to improve how we monitor people at risk of blood cancer, and to help us find better ways to prevent, detect and treat the disease so people can live longer, better lives."
Dr. Jyoti Nangalia, senior author at the Wellcome Sanger Institute and an Honorary Consultant Haematologist at Cambridge University Hospitals NHS Foundation Trust, highlighted the deeply personal aspect of the research: "These are patients we have cared for and followed in our clinic for over 15 years. It can be incredibly difficult to predict how their cancers might change over time. By combining long-term clinical care with regular genomic analysis, we’ve been able to watch how the genetic code of their disease evolves in advance of clinical changes. The patterns we have found will help doctors develop better monitoring strategies, refine diagnosis and lead to better patient outcomes in the long run." Her dual role as researcher and clinician underscores the translational impact of this work, directly connecting laboratory discoveries to improved patient care.
A Patient’s Journey: Three Decades with MPN
The human dimension of this scientific breakthrough is poignantly illustrated by the experiences of patients like Alan Everitt, 77, who has been under the care of Cambridge University Hospitals NHS Foundation Trust for over three decades. Diagnosed in 1992 with essential thrombocythemia (ET), a specific form of MPN characterized by the excessive production of platelets, Mr. Everitt’s journey reflects the complex and often unpredictable nature of these diseases. His condition later progressed to myelofibrosis, marked by the scarring of the bone marrow, and he has also contended with recurrent skin cancers.
Alan Everitt, from Hardwick, Cambridgeshire, shared his perspective: "It’s been reassuring to be cared for over so many years by both the hematology and plastic surgery teams at Addenbrooke’s Hospital in Cambridge. I have always felt well supported and I’m grateful for the care and feedback at every step. Living with a blood cancer for such a long time has come with many challenges, and I hope that taking part in this research will help make a difference for future patients whose cancer is likely to progress over time, as mine has." His participation in the study, spanning years of follow-up and contributing invaluable genomic and clinical data, directly facilitated the discoveries that could benefit countless future patients. His story is a powerful testament to the long-term commitment required for such groundbreaking research and the profound impact it can have on individuals living with chronic diseases.
The collaborative spirit of this research, supported in part by Wellcome and Cancer Research UK, exemplifies the power of interdisciplinary science in tackling complex medical challenges. By meticulously tracking the genetic evolution of chronic blood cancers over decades, this study has not only advanced our fundamental understanding of disease progression but has also laid the groundwork for a new era of personalized medicine in hematology, promising earlier detection, more accurate diagnoses, and ultimately, better outcomes for patients worldwide. The insights garnered from this research are poised to reshape clinical practice, offering a beacon of hope for those living with these intricate and often challenging conditions.
